Menu

• Ask a Health Expert about HYPERVISCOSITY SYNDROME
• Post Your Side Effect related to HYPERVISCOSITY SYNDROME
• HYPERVISCOSITY SYNDROME and FDA Warnings
• HYPERVISCOSITY SYNDROME in Patients Wiki
• Report HYPERVISCOSITY SYNDROME in Drug Side Effect Survey

HYPERVISCOSITY SYNDROME side effect

What is HYPERVISCOSITY SYNDROME ?

A Health Expert wants to answer your question. Please provide details below.

Type your question here

 letters left

Velcade Side Effects Report #5746162-5
Physician from JAPAN reported VELCADE problem on May 08, 2008. Male patient, 76 years of age, was diagnosed with multiple myeloma and was treated with VELCADE. After drug was administered, patient experienced the following problems/side effects: hyperviscosity syndrome, tumour lysis syndrome, . VELCADE dosage: 1 MG/M2, INTRAVENOUS. During the same period patient was treated with DECADRON. Patient died on 04/20/2008.

Velcade Side Effects Report #5390031-X
VELCADE problem was reported by a Physician from GREECE on July 11, 2007. Female patient, weighting 132.3 lb, was diagnosed with multiple myeloma and was treated with VELCADE. After drug was administered, patient experienced the following problems/side effects: disease progression, hyperviscosity syndrome, hyponatraemia, mental status changes, . VELCADE dosage: unknown. Patient was hospitalized and became disabled. Patient recovered.

Velcade Side Effects Report #5390031-X
Physician from GREECE reported VELCADE problem on July 11, 2007. Female patient, weighting 132.3 lb, was diagnosed with multiple myeloma and was treated with VELCADE. After drug was administered, patient experienced the following problems/side effects: disease progression, hyperviscosity syndrome, hyponatraemia, mental status changes, . VELCADE dosage: unknown. Patient was hospitalized and became disabled. Patient recovered.

Revlimid Side Effects Report #5371480-2
REVLIMID problem was reported by a Physician from UNITED STATES on June 19, 2007. Female patient, 70 years of age, was diagnosed with disease progression, multiple myeloma and was treated with REVLIMID. After drug was administered, patient experienced the following problems/side effects: disease progression, hyperviscosity syndrome, multiple myeloma, . REVLIMID dosage: 10 MG, OD X 21 DAYS Q 28 DAYS, ORAL. Patient died on 05/16/2007.


Velcade Side Effects Report #5316527-4
Physician from AUSTRALIA reported VELCADE problem on Apr 18, 2007. Female patient, 78 years of age, was diagnosed with multiple myeloma and was treated with VELCADE. After drug was administered, patient experienced the following problems/side effects: cerebral haemorrhage, disease progression, hyperviscosity syndrome, thrombocytopenia, . VELCADE dosage: 2.30 MG, INTRAVENOUS. During the same period patient was treated with DEXAMETHASONE, ROMIDEPSIN. Patient died on 04/17/2007.